There were amazing stories of brexanolone helping patients with a rare form of epilepsy. But a randomized clinical trial today showed that the drug performed no better than a control group. Shares in its maker, Sage Therapeutics are down 15%.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2017/09/12/does-sage-therapeutics-failure-predict-its-future-results/
via IFTTT
No comments:
Post a Comment